(Q35147065)

English

Alemtuzumab

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

6 August 2017

1 reference

Europe PubMed Central

Alemtuzumab. (English)

1 reference

Europe PubMed Central

6 August 2017

Antona J Wagstaff

2

object named as

Antona J Wagstaff

1 reference

Europe PubMed Central

6 August 2017

author name string

James E Frampton

1

1 reference

Europe PubMed Central

6 August 2017

publication date

1 January 2003

1 reference

Europe PubMed Central

6 August 2017

1 reference

Europe PubMed Central

6 August 2017

63

1 reference

Europe PubMed Central

6 August 2017

12

1 reference

Europe PubMed Central

6 August 2017

1229-43; discussion 1245-6

1 reference

Europe PubMed Central

6 August 2017

https://scigraph.springernature.com/pub.10.2165/00003495-200363120-00003

0 references

New Directions in the Diagnosis and Treatment of Chronic Lymphocytic Leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monoclonal antibody-based therapy of lymphoid neoplasms: what's on the horizon?

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

T-cell prolymphocytic leukemia: update and focus on alemtuzumab (Campath-1H).

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo 'Purging' of residual disease in CLL with Campath-1H

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of Campath-1H antibody on human hematopoietic progenitors in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

T cell depletion of allogeneic stem cell grafts with anti-CD 52 monoclonal antibodies: the Ulm experience from 1983-1999.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Humanized CD52 monoclonal antibody campath-1H as first-line treatment in chronic lymphocytic leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

T-cell Prolymphocytic Leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Campath-1H in B-chronic lymphocytic leukemia: report on a patient treated thrice in a 3 year period

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The CAMPATH-1 antigen (CDw52)

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

What choices are available for treatment of the patient with chronic lymphocytic leukemia who is fludarabine-refractory?

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A personal history of the CAMPATH-1H antibody

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alemtuzumab in T-cell malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Future prospects for alemtuzumab (MabCampath).

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Future strategies toward the cure of indolent B-cell malignancies. New biologic therapies

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Emergence of CD52-, phosphatidylinositolglycan-anchor-deficient T lymphocytes after in vivo application of Campath-1H for refractory B-cell non-Hodgkin lymphoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunological effects and safe administration of alemtuzumab (MabCampath) in advanced B-cLL.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alemtuzumab (Millennium/ILEX).

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monoclonal antibodies in the treatment of malignancy: basic concepts and recent developments

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Campath-1H monoclonal antibody therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monoclonal antibody therapies in leukemias

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunotherapy of chronic lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CAMPATH (alemtuzumab) for the treatment of chronic lymphocytic leukemia and beyond

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Current and developing chemotherapy for CLL.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CAMPATH-1 antibodies in stem-cell transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reduced-intensity allogeneic hematopoietic stem cell transplantation with alemtuzumab conditioning regimens: survival does not plateau until after day 200

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Progress in CLL, chemotherapy, antibodies and transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alemtuzumab in stem cell transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Management of chronic lymphocytic leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antibody-based therapy of human leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phenotypic transformation of CD52(pos) to CD52(neg) leukemic T cells as a mechanism for resistance to CAMPATH-1H.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Emerging Therapies: Spectrum of Applications of Monoclonal Antibody Therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alemtuzumab: a new option for refractory chronic lymphocytic leukemia?

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of CAMPATH-1H in BMT patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of CAMPATH-1H: assay development and validation

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Current status of monoclonal antibody therapy for chronic lymphocytic leukemia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clonal CD8+ and CD52- T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52)

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Advances in immunotherapy of hematologic malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical trials with CAMPATH-I and other monoclonal antibodies

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic potential of rat monoclonal antibodies: isotype specificity of antibody-dependent cell-mediated cytotoxicity with human lymphocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/12790693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00003495-200363120-00003

1 reference

Europe PubMed Central

6 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

6 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35147065&oldid=1980095822"